This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

265 result(s)

Ellipta inhaler

27-11-2015
Ellipta inhaler information for UK healthcare professionals including getting started, how to use the Ellipta inhaler and top tips for your patients.

Homepage

GSKpro is exclusively created for healthcare professionals to provide GSK product related information, services and support.

Therapy areas

GSK UK therapy areas page allows healthcare professionals to find GSK product information by therapy area.

Request a contact

Contact us form for UK healthcare professionals to contact GSK

Contact us

GSK UK contact page for healthcare professionals

Video Testimonials: I've Seen Meningitis

Video testimonials from healthcare professionals about the impact of meningitis

Requip & Adartrel (Ropinirole) artwork change | GSKpro

Information for changes to the colour of the ink on both the cartons and blister packs of Requip and a blister pack of Adartrel.

Medicines management and optimisation

Access bespoke financial and prescribing data for your health economy. Identify variability, track and optimise your implementation projects

Respiratory

Overview of Asthma and COPD

Ordering and delivery

Find out how to set up an account and start ordering GSK vaccines.

Varilrix

Varilrix – Chickenpox/varicella vaccine product information to support UK healthcare professionals

Seretide inhaler technique and safety

Videos and materials to help you ensure your patients are using their Seretide Accuhaler and Evohaler correctly.

Adartrel

Adartrel (ropinirole hydrochloride) - links to the summary of product characteristics, patient information leaflet and supply information to support UK healthcare professionals.

COPD

Overview of COPD

Oncology Expert Insights

Expert opinion on ovarian cancer treatment to support UK healthcare professionals

Sitemap

GlaxoSmithKline (GSK) UK healthcare professional website site map.

Report Adverse Event

Form for UK healthcare professionals to report an adverse event related to a GSK product

GSK Highlights from ATS 2020 | GSKpro

GSK Highlights from The American Thoracic Society (ATS) Congress 2020

Home | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals

Vaccines

GSK UK information about our vaccines and disease awareness campaigns

DECTOVA▼

Zanamivir IV</br> Influenza

COPD expert perspectives

Watch GSK Global Medical Experts approach key issues in COPD treatment, offering solutions for UK healthcare professionals.

Asthma expert perspectives

Watch GSK Global Medical Experts approach key issues in asthma treatment, offering potential solutions for you and your patients

Asthma

Overview of Asthma

Ellipta critical error studies in asthma

Information about the benefits of GSK's Ellipta inhaler for UK healthcare professionals to support their asthma patients

Ellipta inhaler products

Ellipta inhaler product information for UK healthcare professionals including an overview of the medicines available in the Ellipta device.

Ellipta critical error studies in COPD

Information about the benefits of GSK's Ellipta inhaler for UK healthcare professionals to support their COPD patients

Patient stories | Seretide (salmeterol/fluticasone propionate)

Patient stories with Seretide Evohaler (salmeterol/fluticasone propionate)

Cost | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) price information to support UK healthcare professionals

Dose & Device | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) dosing and device information to support UK healthcare professionals

Guidelines |Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)| GSKPro

Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals

Identifying patients | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals

Safety Information | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals

HRQoL | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals

Lung Function | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) I COPD I GSKPro

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals

Efficacy

Trelegy Ellipta is a Triple Therapy indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA.

Molecules | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals

Efficacy | Nucala (mepolizumab)

Read the clinical data about Nucala (mepolizumab).

Nucala (meplizumab) | Severe eosinophilic asthma

Learn more about Nucala (mepolizumab) as an add-on treatment for patients with severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.

Resources | Nucala (mepolizumab)

View other resources to support you and your patients using Nucala (mepolizmab) as an add on treatment for adults, adolescents and children over 6 years old with severe refractory eosinophilic asthma.

Expert Perspectives | Nucala (mepolizumab)

See what the experts have to say about Nucala (mepolizumab).

Safety Information | Nucala (mepolizumab)

See the safety profile of Nucala (mepolizumab) in adults and adolescents.

Paediatric Patients | Nucala (mepolizumab)

See the data behind and safety profile of Nucala (mepolizumab) in paediatric patients with severe asthma.

Identifying Patients | Nucala (mepolizumab)

Understand how to identify which patients with severe asthma are suitable for treatment with Nucala (mepolizumab) as an add-on treatment.

Dosing & Administration | Nucala (mepolizumab)

Nucala (mepolizumab) can be administered at home or in clinic. Read more about dosing and administration here.

Zejula▼

Niraparib

Products

GSK product information for UK healthcare professionals

GSK support for healthcare professionals in response to COVID-19

Information for healthcare professionals on GSK’s response to COVID-19, where to find support and relevant resources.

GSK Highlights from ERS 2020 | GSKpro

GSK Highlights from European Respiratory Congress 2020

Safety Information | Nucala (mepolizumab)

See the safety profile of Nucala (mepolizumab) in adults and adolescents.

Dosing & Administration | Nucala (mepolizumab)

Nucala (mepolizumab) can be administered at home or in clinic. Read more about dosing and administration here.

Resources | Nucala (mepolizumab)

View other resources to support you and your patients using Nucala (mepolizmab) as an add on treatment for adults, adolescents and children over 6 years old with severe refractory eosinophilic asthma.

Identifying Patients | Nucala (mepolizumab)

Understand how to identify which patients with severe asthma are suitable for treatment with Nucala (mepolizumab) as an add-on treatment.

Expert Perspectives | Nucala (mepolizumab)

See what the experts have to say about Nucala (mepolizumab).

Nucala (meplizumab) | Severe eosinophilic asthma

Learn more about Nucala (mepolizumab) as an add-on treatment for patients with severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.

Discontinued products | GSK Pro

Discontinued products

Paediatric Patients | Nucala (mepolizumab)

See the data behind and safety profile of Nucala (mepolizumab) in paediatric patients with severe asthma.

Supply

Information to be provided to Healthcare Professionals on GSK’s medicines and vaccines supply availability

Products

GSK product information for UK healthcare professionals

FAQ | Supply | GSKpro

Frequently asked questions around the supply and availability of GSK medicines and vaccines.

Efficacy | Nucala (mepolizumab)

Read the clinical data about Nucala (mepolizumab).

No results. Why not try:

  • Checking the spelling of the search term
  • Trying a different search term
  • Resetting or revising the filter settings (if you used filters to do this search)

Show more